PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

Detalles Bibliográficos
Autores principales: Palandri, Francesca, Gröpper, Stefanie, Loschi, Michael, Bellesso, Marcelo, Grosicki, Sebastian, Giraldo, Pilar, Harrison, Claire, Clevenger, Tracy, Stuart, Nikki, Qamoos, Hope, Vosganian, Gregory, Rothbaum, Wayne P., Verstovsek, Srdan, Vachhani, Pankit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428783/
http://dx.doi.org/10.1097/01.HS9.0000975544.01102.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428783/
http://dx.doi.org/10.1097/01.HS9.0000975544.01102.10

Ejemplares similares